| introduction | nemolizumab (Nemolizumab), a biological preparation for atopic dermatitis, is a humanized monoclonal antibody targeting interleukin 31. molizumab is still under development, and the phase III clinical study of the drug was successful in July 2020. |
| target; Species | IL13[Homo sapiens] |
| Use | Leretien monoclonal antibody has been used to study trials for the treatment of asthma, allergic asthma, atopic dermatitis, idiopathic pulmonary fibrosis and COPD (chronic obstructive pulmonary disease). |
| adverse reactions | the main adverse events were conjunctivitis, and other common adverse events were upper respiratory tract infection, nasopharyngitis, headache and pain at the injection site. |